Table 3 Multivariate survival analyses.
From: Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma
Parameter | Category | OS | LRFS | ||||
|---|---|---|---|---|---|---|---|
RR | 95% CI | p-value | RR | 95% CI | p-value | ||
IL-20 | Low expression | 1 | — | 0.030* | 1 | — | 0.011* |
High expression | 3.025 | 1.110–8.241 | 2.348 | 1.211–4.553 | |||
Pugh-Child’s Classification | A | 1 | — | 0.003* | 1 | — | 0.204 |
B | 6.048 | 0.700–52.259 | 1.546 | 0.281–8.492 | |||
C | 22.748 | 2.785–185.791 | 3.581 | 0.830–15.451 | |||
CLIP score | 0–1 | 1 | — | 0.939 | 1 | — | 0.012* |
2–3 | 1.046 | 0.324–3.379 | 3.159 | 1.293–7.719 | |||
AJCC Stage | Stage I | 1 | — | 0.004* | 1 | — | 0.027* |
Stage II | 2.678 | 0.607–11.813 | 2.667 | 1.280–5.555 | |||
Stage III-V | 8.788 | 2.406–33.489 | 2.082 | 0.828–5.237 | |||
Okuda stage | I | 1 | — | 0.878 | — | — | — |
II-III | 1.081 | 0.341–2.506 | — | — | — | ||
Differentiation | Well/Moderately differentiated | 1 | — | 0.486 | 1 | — | 0.623 |
Poorly differentiated | 1.592 | 0.170–2.324 | 1.270 | 0.304–2.042 | |||
